A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: principles (564), values (295)

Epcoritamab -Cycle 2 (Onwards)

Description
Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Epcoritamab -Cycle 1 (Priming)

Description
Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

SETT Clinical Theme lead PS v2

Description
EMPLOYMENT CRITERIA/PERSON SPECIFICATION The purpose of this specification is to identify the attributes required by applicants to perform the duties de
Url
/Media/Southampton-Clinical-Research/Downloads/SETT-Clinical-Theme-lead-PS-v2.pdf

Following your successful food challenge - patient information

Description
This factsheet explains what to expect following your successful food challenge.
Url
/Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Following-your-successful-food-challenge-3264-PIL.pdf

Avelumab-Axitinib

Description
Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectable locally advanced or metastatic renal cell carcinoma (RCC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

Carboplatin and Vinorelbine (intravenous)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN-VINORELBINE (Intravenous) Regimen • NSCLC – Carboplatin-Vinorelbine (intravenous) Indication • First line therapy of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinandVinorelbineintravenous.pdf

About your wig prescription - patient information

Description
If you are diagnosed with a dermatological condition that causes significant hair loss, the Southampton Dermatology Centre will give you a
Url
/Media/UHS-website-2019/Patientinformation/Skin/About-your-wig-prescription-1201-PIL.pdf

UHS Our People Strategy 2022 - 2026

Description
OUR PEOPLE STRATEGY 2022 to 2026 CONTENTS 05 Foreword by Steve Harris – chief people officer 06 Our strategic framework 07 Always
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Plans-and-strategies/UHS-Our-People-Strategy-2022-2026.pdf

Mechanical thrombectomy - patient information

Description
This factsheet contains information about a procedure known as a 'mechanical thrombectomy'.
Url
/Media/UHS-website-2019/Patientinformation/Brain-and-spine/Mechanical-thrombectomy-1957-PIL.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description
Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf
221 to 230 of 427
Previous … 21 22 23 24 25 … Next